SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) announced on November 18, 2026, the pricing of an underwritten public offering. The company sold 11,538,462 shares of its common stock at a price of $13.00 per share. The total gross proceeds from this sale are expected to be $150.0 million, before deducting underwriting discounts and commissions and offering expenses.

Under the terms of the underwriting agreement, the underwriters have been granted a 30-day option to purchase up to 1,730,769 additional shares of common stock at the same public offering price. If the underwriters exercise this option in full, the total number of shares sold could increase to 13,269,231.

The offering is being conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the SEC on March 20, 2026, and became automatically effective upon filing. The offering is expected to close on or about November 20, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan Securities LLC and TD Cowen are serving as the lead book-running managers for the transaction. Mizuho is acting as a book-running manager, while A.G.P./Alliance Global Partners and Maxim Group LLC are serving as lead managers.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for cancer indications. The company’s lead product candidate, GPS, targets the WT1 protein and is licensed from Memorial Sloan Kettering Cancer Center. Additionally, the company is developing SLS009 (tambiciclib), a small molecule CDK9 inhibitor, for the treatment of AML in patients with unfavorable prognostic factors.